title: [Transcatheter arterial chemoembolization in the treatment of hepatocellular carcinoma].
abstract: OBJECTIVE
  To evaluate the effect of transcatheter arterial chemoembolization (TACE) on the result and the prognosis of hepatocellular carcinoma (HCC) at systemic, cellular, genetic and molecular levels.
  
  
  METHODS
  Patients with histologically proven HCC were divided into two groups: 81 patients in Group A undergoing TACE before operation and 58 patients in Group B treated with surgical resection alone. The degree of apoptosis was analyzed by transferase -mediated dUTP nick end labeling (TUNEL) stain. The expressions of bcl-2, bax, p53, Ki-67 and PCNA proteins were detected by immunohistochemical method. The changes of these markers, tumor necrosis, encapsulation, volume, metastasis, recurrence and cumulative survival in each group were retrospectively analyzed.
  
  
  RESULTS
  The more tumor necrosis, apoptosis, encapsulation and tumor shrinkage observed, and the less recurrence resulted from TACE in group A than in group B. The cumulative 1-, 2-, and 3-year survival rates and median survival time were 84.0%, 67.9%, 40.7%, and 803.3 days in group A patients; they were 72.4%, 55.2%, 24.1%, and 742.5 days in group B patients (P < 0.05).
  
  
  CONCLUSIONS
  Preoperative transcatheter arterial chemoembolization is safe and effective as an auxiliary preparatory means before surgical treatment of hepatocellular carcinoma as it may improve the survival of HCC patients.
authors.affiliation: Department of Radiology, Second Xiangya Hospital, Xiangya Medical College, Central South University, Changsha 410011, China. cjr.xiaoenhua@vip.163.com
authors.forename: En-hua
authors.initials: EH
authors.lastname: Xiao
authors.forename: Guo-dong
authors.initials: GD
authors.lastname: Hu
authors.forename: Jin-qing
authors.initials: JQ
authors.lastname: Li
authors.forename: Jie-fu
authors.initials: JF
authors.lastname: Huang
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage; D006528:Carcinoma, Hepatocellular / Q000628:therapy*; D016461:Chemoembolization, Therapeutic; D005260:Female; D006499:Hepatic Artery; D006801:Humans; D008113:Liver Neoplasms / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D011379:Prognosis